Dianthus Therapeutics (DNTH) Common Equity (2017 - 2025)

Dianthus Therapeutics' Common Equity history runs 9 years deep, the most recent figure standing at $493.4 million for Q4 2025.

• In Q4 2025, Common Equity rose 39.98% year-over-year to $493.4 million; the TTM figure through Dec 2025 stood at $493.4 million (up 39.98% YoY), while the FY2025 annual figure was $493.4 million, up 39.98% from the prior year.
• Common Equity was $493.4 million for Q4 2025 at Dianthus Therapeutics, down from $546.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $546.5 million in Q3 2025 to a low of -$61.5 million in Q2 2023.
• Historically, Common Equity has averaged $185.2 million across 5 years, with a median of $184.0 million in 2021.
• The sharpest annual moves came in 2022 and 2024: Common Equity slumped 157.22% in 2022, then surged 833.35% in 2024.
• A 5-year view of Common Equity shows it stood at -$17.2 million in 2021, then sank by 157.22% to -$44.4 million in 2022, then soared by 480.61% to $168.9 million in 2023, then surged by 108.73% to $352.5 million in 2024, then surged by 39.98% to $493.4 million in 2025.
• The last three Common Equity figures came in at $493.4 million (Q4 2025), $546.5 million (Q3 2025), and $303.1 million (Q2 2025), per Business Quant data.